Press Releases

Date	Title	PDF Version
Jan 26, 2017	Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results on Thursday, February 16, 2017
Jan 09, 2017	Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
Jan 06, 2017	FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Jan 05, 2017	Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 04, 2017	Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016
Dec 21, 2016	Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation
Dec 12, 2016	Alexion's Board of Directors Announces New Leadership Appointments
Dec 04, 2016	New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Nov 29, 2016	Alexion to Present at the Citi 2016 Global Healthcare Conference
Nov 17, 2016	New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris® (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant

Search